Search

With the emergence of the COVID-19 pandemic, pharmaceutical companies and physicians are exploring extensive research initiatives to identify agents, compounds, and other therapeutic approaches. Consideration has been given to the repurposing of older medicinal agents and using traditional agents to control the inflammatory process preceding viral pneumonia development and lung damage. Several monoclonal antibody cocktails have received EUA approval, and convalescent plasma remains a favorable option in hospitalized patients. To date, remdesivir is the only FDA pharmaceutical on the market to treat patients with a diagnosis of COVID-19. The purpose of this review is to discuss some current pharmaceutical options, approved and developing, currently used in the treatment of COVID-19. [ABSTRACT FROM AUTHOR]

Casirivimab/imdevimab, a cocktail of monoclonal antibodies, is currently approved for emergency use in high-risk ambulatory patients with early COVID-19 to reduce risk of hospitalization and/or death from SARS-CoV-2 infection. In the United States, there is no approved monoclonal antibody therapy for patients hospitalized for complications due to acute SARS-CoV-2 infection. We describe here the use of casirivimab/imdevimab in a 52-year-old fully vaccinated, immunocompromised man admitted to the intensive care unit for acute hypoxemic respiratory failure due to SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]